Pilot corpus: NIH-funded biomedical datasets. Any DOI can be scored on demand — network effects sharpen as coverage grows.

Cabotegravir for the prevention of HIV-1 in women: results from HPTN 084, a phase 3, randomised clinical trial

The Lancet(2022)10.1016/s0140-6736(22)00538-4Source: DataRank Database

Cabotegravir for the prevention of HIV-1 in women: results from HPTN 084, a phase 3, randomised clinical trial is a research paper published in The Lancet (2022). On theSindex it has a DataRank of 7.4. It has been cited 552 times, with 100 citing works in its 1-hop citation network.

N/A

7.4DataRank · unranked

Scored on demand from live citation data

Deposits data Open Access552 citations · 100 citing works in its network

Free full text

Cite:

Data availability

Repositories this paper deposited data in (declared in PubMed).

ClinicalTrials.govNCT03164564

DataRank reads this dataset's downstream impact straight off the citation graph — no black box, no proprietary weighting. How is this computed?

›Methodology & internals

datarank_citation_only_1hop_v6· scope data_onlyMethodology

Pipeline:MetadataData-paper checkEnrichmentCitation networkScoring

Enrichment:Funding (19 grants)Impact (FWCI 46.82)OA: hybridTopics (66)IDs (PubMed, OpenAlex)SDGs (3)

FAIR Checklist

Context only (not used in score)

Findable (1/2)

Has DOI

Accessible (1/2)

Open Access

Interoperable (0/2)

Reusable (0/3)

FAIR checklist signals are shown for context only and do not affect DataRank scoring.

Run a calibrated FAIR evaluation for this paper →

We only score data papers we can read in full — never from an abstract alone.

DataRank Breakdown

Base Score 13%Citation Network 87%

Base Score Contribution

0.947

From this paper's citation signal

Citation Network Contribution

6.5

From 100 citing papers with measurable signal

Learn more about DataRank methodology →

Top 5 citers driving the network score

Ranked by each citer's contribution to N(p) — log1p(C_q) divided by its reference count — out of 100 citers.

Long‐acting injectable cabotegravir: implementation science needed to advance this additional HIV prevention choice
Journal of the International AIDS Society202229 citations11 referencesContributes 0.309
Ending the HIV Epidemic for Persons Who Use Drugs: the Practical Challenges of Meeting People Where They Are
Journal of General Internal Medicine202315 citations9 referencesContributes 0.308
Long-Acting Injectable Cabotegravir and Rilpivirine in a Pregnant Woman With HIV
Clinical Infectious Diseases202426 citations14 referencesContributes 0.235
Pharmacokinetics and safety of once-yearly lenacapavir: a phase 1, open-label study
The Lancet202547 citations18 referencesContributes 0.215
Why is roll-out of long-acting PrEP agents so slow?
Current Opinion in HIV and AIDS202418 citations15 referencesContributes 0.196

Authors (100)

James P. Hughes ORCID,Peter Bock ORCID,Samuel Gurrion Ouma ORCID,Portia Hunidzarira ORCID,Dishiki Kalonji

Live enrichment

PubMed:35378077 OpenAlex:https://openalex.org/W4226116413

National Institute of Allergy and Infectious Diseases

Grant: UM1AI068613

National Institute of Allergy and Infectious Diseases

Grant: UM1AI068617

National Institute of Allergy and Infectious Diseases

Grant: UM1AI068619

Bill and Melinda Gates Foundation

Grant: OPP1154174

National Institutes of Health

Grant: 5UM1AI068619-09

LOC: HIV Prevention Trials Network

National Institutes of Health

Grant: 3UM1AI068617-20S1

HPTN SDMC: HPTN 096 Getting to Zero among Highest HIV Incidence (HHI) Men who have Sex with Men (MSM) in the American South: Testing an Integrated Strategy

National Institutes of Health

Grant: 5UM1AI068613-16

LC: HIV PREVENTION TRIALS NETWORK

NIAID NIH HHS

Grant: UM1 AI069423

NIAID NIH HHS

Grant: UM1 AI069456

NIAID NIH HHS

Grant: UM1 AI069518

NIAID NIH HHS

Grant: UM1 AI069453

NIAID NIH HHS

Grant: UM1 AI069463

NIAID NIH HHS

Grant: UM1 AI154468

NIAID NIH HHS

Grant: UM1 AI069436

NIAID NIH HHS

Grant: U01 AI069436

NIAID NIH HHS

Grant: UM1 AI069469

NIAID NIH HHS

Grant: UM1 AI069530

NIAID NIH HHS

Grant: UM1 AI069521

NIAID NIH HHS

Grant: P30 AI050410

FWCI

46.82

Citation Percentile

1.0%

Citation Trend

2022

2023

2024

2025

2026

hybridLicense: cc-by

journalhttps://doi.org/10.1016/s0140-6736(22)00538-4

publisherhttps://doi.org/10.1016/s0140-6736(22)00538-4

publisherhttps://api.elsevier.com/content/article/PII:S0140673622005384?httpAccept=text/xml

publisherhttps://api.elsevier.com/content/article/PII:S0140673622005384?httpAccept=text/plain

repositoryhttps://pubmed.ncbi.nlm.nih.gov/35378077

Fields of Study

HIV/AIDS Research and InterventionsReproductive tract infections researchHIV, Drug Use, Sexual Risk0301 basic medicine03 medical and health sciences0302 clinical medicineAdultFemaleHumansPregnancyAnti-HIV AgentsDiketopiperazinesEmtricitabineHIV InfectionsHIV SeropositivityHIV-1PyridonesMaleAdolescentYoung AdultMiddle Aged

MeSH Terms

EmtricitabineAdolescentAdultChildFemaleHIV SeropositivityHumansInfant, NewbornMaleMiddle AgedPregnancyPyridonesHIV-1HIV InfectionsAnti-HIV AgentsDiketopiperazinesYoung Adult

Keywords

EmtricitabineMedicineHuman immunodeficiency virus (HIV)PillPre-exposure prophylaxisTenofovirClinical trialInternal medicineFamily medicinePharmacologyAntiretroviral therapyViral loadMen who have sex with menAdultMaleAdolescentAnti-HIV AgentsPyridonesHIV InfectionsArticlesDiketopiperazinesMiddle AgedYoung AdultPregnancyHIV SeropositivityHIV-1HumansFemale

Sustainable Development Goals

SDG 3: 3. Good healthSDG 16: 16. Peace & justiceSDG 0: Good health and well-being